NEMUS Bioscience Is Now Quoted on the OTC Bulletin Board Under the Ticker Symbol of “NMUS”

Biopharmaceutical Company Developing Cannabis-Based Medicines with the University of Mississippi

COSTA MESA, Calif.--(BUSINESS WIRE)-- NEMUS Bioscience, Inc. a Nevada corporation (the “Company”), announced that its common stock is now eligible for quotation on the OTC Bulletin Board under the ticker symbol (NMUS). NEMUS completed a reverse merger with Load Guard Logistics, Inc. (“LGL”), a Nevada corporation, on October 31, 2014. During the transition period, the Company’s common stock had been quoted under the symbol LGLRD.

In connection with the merger, LGL issued a total of 12,880,000 shares of common stock in exchange for all of the outstanding shares of common stock of NEMUS and LGL thereafter repurchased and retired 5,431,460 shares of common stock from the company’s former officers and directors in exchange for all of the issued and outstanding shares of LGT, Inc., LGL’s historical operating subsidiary. Following the completion of the merger and the retirement of the shares of LGL, the Company has a total of 16,000,000 shares of common stock issued and outstanding. As a result of the transaction contemplated by the Merger Agreement, the Company’s sole business operations are that of NEMUS.

NEMUS is a biopharmaceutical company focused on the discovery, development and commercialization of cannabis-based therapeutics. The Company is currently the sole partner of the University of Mississippi for the development and commercialization of drugs derived from cannabis extracts, or cannabinoids, and the realization of this partnership will depend on the successful navigation of the complex regulatory framework for the cultivation and handling of cannabis in the United States. The University of Mississippi has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968.

About NEMUS Bioscience, Inc.

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabis-based therapeutics for global markets with significant unmet medical needs. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS’s strategy is not limited to the sole use of either natural or synthetic inputs.

The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit www.nemusbioscience.com.

Forward Looking Statements

Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “goal,” “focus,” “aims,” “believes,” “can,” “challenge,” ”predictable,” “will,” or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.

NEMUS Bioscience
Investor relations, 818-377-7426
or
Media Contact:
Evolve!, Inc.
Jenna Dobkin, 415-652-2185
jenna@evolvesinc.com

Source: NEMUS Bioscience, Inc.

Released November 26, 2014